Vesal­ius gets to work on €120M Fund III — ex­pect more on wom­en's health, on­col­o­gy

Vesal­ius Bio­cap­i­tal, a Eu­ro­pean VC play­er that’s bet along­side the cor­po­rate ven­ture arms of No­var­tis, No­vo and Mer­ck KGaA, has closed its third fund with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.